The key objectives of this grant are to mentor junior investigators to conduct hypothesis-driven research projects related to colorectal cancer (CRC) prevention. I will utilize my research program and its areas of focus to achieve this objective that will involve mentoring investigators in the following areas: 1) an interventional chemoprevention trial;2) the study of prognostic and predictive biomarkers, inclusive of epidemiological factors, in relation to cancer outcomes in adjuvant treatment trials;and 3) novel therapeutic strategies for chemoprevention with a focus on apoptotic signaling pathways as molecular targets. These projects represent significant opportunities to conduct timely and clinically important research that builds upon a successful program that utilizes a high risk study population and a unique tissue resource and database from a cancer cooperative group. My overall mentoring objectives are to improve the research knowledge, skills, professional maturity, and academic productivity of junior investigators that will enable them to become independent investigators and future leaders in cancer prevention and control. The K05 grant will also serve another important objective of providing increased protected time for the principal investigator to pursue and expand his ongoing translational research efforts in colorectal cancer that can lead to programmatic expansion and additional extramural funding. Increased protected time will also facilitate my commitment to mentoring and enable me to continue to make important contributions that serve to advance the field of cancer prevention. The end product of these efforts is the potential to reduce cancer incidence and recurrence, thus eliminating suffering related to colorectal cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Scientist Award (K05)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Perkins, Susan N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Tougeron, David; Sha, Dan; Manthravadi, Sashidhar et al. (2014) Aspirin and colorectal cancer: back to the future. Clin Cancer Res 20:1087-94
Sha, Dan; Lee, Adam M; Shi, Qian et al. (2014) Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res 20:3319-27
Yoon, Harry H; Sukov, William R; Shi, Qian et al. (2014) HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer 120:415-24
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43
Zaanan, Aziz; Bachet, Jean-Baptiste; André, Thierry et al. (2014) Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon Cancer. Curr Colorectal Cancer Rep 10:346-353
Sweetser, Seth; Smyrk, Thomas C; Sinicrope, Frank A (2013) Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol 11:760-7; quiz e54-5
Sinicrope, Frank A; Foster, Nathan R; Yothers, Greg et al. (2013) Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer 119:1528-36
Sinicrope, Frank A; Mahoney, Michelle R; Smyrk, Thomas C et al. (2013) Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 31:3664-72
Sinicrope, Frank A; Smyrk, Thomas C; Tougeron, David et al. (2013) Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer 119:2765-70
Park, Jae Myung; Huang, Shengbing; Tougeron, David et al. (2013) MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One 8:e65369

Showing the most recent 10 out of 20 publications